anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
Many diarrhea-causing pathogens are climate-sensitive, and populations with the lowest socioeconomic position (SEP) are often most vulnerable to climate-related transmission. Household Water, Sanitation, and Handwashing (WASH) interventions constitute one potential effective strategy to reduce child diarrhea, especially among low-income households. Capitalizing on a cluster randomized trial population (360 clusters, 4941 children with 8440 measurements) in rural Bangladesh, one of the world's most climate-sensitive regions, we show that improved WASH substantially reduces diarrhea risk with largest benefits among children with lowest SEP and during the monsoon season. We extrapolated trial results to rural Bangladesh regions using high-resolution geospatial layers to identify areas most likely to benefit. Scaling up a similar intervention could prevent an estimated 734 (95% CI 385, 1085) cases per 1000 children per month during the seasonal monsoon, with marked regional heterogeneities. Here, we show how to extend large-scale trials to inform WASH strategies among climate-sensitive and low-income populations.
Explanation for choice of comparators {6b} The telematics multidisciplinary approach (experimental group) will be compared to Standard of Care (SoC) (control group). SoC consists of a patient's follow up according to the usual clinical practice. In Bellvitge University Hospital's setting, the treatment protocol for CnsLBP indicates physical rehabilitation/physiotherapy as the first treatment step, and Pain Clinic evaluation as a second step for those who did not improve. For patients who did not improve with the previous steps and that still demand a solution for their CnsLBP, a third step would be to refer the patient for surgical evaluation - a spine surgeon would, then, evaluate, alongside with the patient, whether a surgical approach would be appropriate for his/her case. If the surgery is ruled out by the spine surgeon, the patient may be referred, once more, to physical rehabilitation/physiotherapy and/or to the Pain Clinic, at the surgeon's discretion.
Background and Objectives: Postmenopausal vaginal discomfort is often attributed to vulvovaginal atrophy (VVA). Women with VVA experience symptoms such as vaginal dryness, itching, burning, irritation, and dyspareunia. Materials and Methods: This pilot study was conducted to assess the effects of a micro-ablative fractional CO2 laser on the clinical symptoms of VVA, as well as concordant sexual function. The severity of VVA symptoms was evaluated by a visual analogue scale (VAS), while the condition of the vaginal mucosa was evaluated using the Vaginal Health Index Score (VHSI). Sexual function was evaluated using the Female Sexual Function Index (FSFI) Questionnaire. Results: Our cohort included 84 sexually active postmenopausal women with bothersome VVA, leading to sexual health complaints. The mean age of the participants in our study was 55.2 ± 5.4 years, with an average postmenopausal period of 6 ± 4.8 years. The age of our patients and the length of their postmenopausal period exhibited a significant negative correlation with VHSI scores, while a longer postmenopausal period was associated with increased severity of vaginal dryness and dyspareunia. Baseline VHSI values showed that 65% of patients had atrophic vaginitis with pronounced VVA symptoms (70.2% experienced vaginal itching, 73.8% reported vaginal burning, 95.3% had vaginal dryness, and 86.1% suffered from dyspareunia). Lower VHSI values significantly correlated with lower FSFI scores, while more severe VVA symptoms scores correlated with lower FSFI scores. VVA symptoms were significantly less severe after treatment. VHIS regained high non-atrophic values in 98.8% of patients post-treatment (p < 0.001). FSFI total and domain scores were significantly higher after treatment (p < 0.001). Conclusions: Our study revealed that fractional CO2 laser is a useful treatment option to alleviate VVA symptoms and improve vaginal health and sexual functioning in postmenopausal women.
Women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection, or a frozen-thawed embryo transfer as first line over a fresh embryo transfer, if clinically indicated. Embryo selection for transfer will be based on morphological criteria.
Suppositories based on indomethacin (I) contain a unit dose of (I) in combination with a hydrophilic carrier comprising fatty acid esters. The unit dose of (I) is pref. 25-200 (esp. 25-100) mg. The carrier is pref. a prod. obtained by direct esterification of glycerol and polyoxyethylene glycol with natural fatty acids, esp. "Suppocire AP". The suppositories can be prepd. by heating the carrier to 35-40 deg.C, adding (I), pouring the mixt. into capsules, and allowing to cool to room temp. (I) has antiinflammatory and analgesic activity. Hydrophilic ester carriers have good rectal absorption properties (comparable to conventional polyethylene glycol carriers) together with good local tolerance.
The only group consists of participants with moderate to severe OUD who will be starting treatment with extended-release injectable buprenorphine as part of standard of care. While individual treatment regimens may vary, these will often consist of 2 once-monthly 300 mg subcutaneous injections followed by 4 once-monthly 100 mg subcutaneous injections. However, participants may receive once-monthly 300 mg subcutaneous injections in place of 100 mg subcutaneous injections for as many months as is deemed necessary by their prescribing physician.
Concomitant use of atazanavir and nelfinavir with proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and may result in a loss of therapeutic effect and the development of drug resistance. Co-administration of saquinavir with proton pump inhibitors is expected to increase saquinavir concentrations, which may increase toxicity and require dose reduction. 

Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19.

Reduced concentrations of atazanavir and nelfinavir 

For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.

Increased concentrations of saquinavir 

For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported, with an increase in AUC by 82%, in Cmax by 75%, and in Cmin by 106%, following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15. Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with omeprazole. Dose reduction of saquinavir should be considered from the safety perspective for individual patients.

There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole.
Down syndrome (DS) is the most common cause of mental retardation due to chromosome anomaly. Besides defects in cognition, DS patients after 30 yeas old will have early dementia. Etiology of early dementia is known to be related with APP gene dosage triplication that is similar to the neuropathological change in Alzheimer disease (AD). It has been known that the cognitive degeneration in AD is related with decrement of cholinergic neurons in the brain. And the clinical improvement or delay in degeneration of cognitive function after utilization of cholinesterase inhibitor had been observed in mild to moderate AD patients. In DS brain, it has been also noted to be lower acetylcholine, supporting the relationship of pathology between DS and AD. Since 1999, Kishnani et al started to treat adult DS patients with cholinesterase inhibitor (Donepezil). Data showed the improvement of cognition and life quality in DS patients with dementia. Recently, data showed the low cholinergic neuron in DS brain might be a cause of cognitive dysfunction in DS. Therefore, early treatment of cholinesterase inhibitor in DS patients had been proposed to alleviate cognitive dysfunction. Since 2004, Kishnani et al started to treat DS children with Donepezil and Rivastigmine. Some patients showed improvement of language ability, memory, and attention. We are going to conduct a randomized, double-blind, placebo-controlled, crossover design, 12-month trial. Subjects who are enrolled in this study will be randomized into two groups. Each group will receive Rivastigmine and placebo in different order for 6 months. Neuropsychological assessment including Vineland Adaptive Behavior Scales and NEPSY will be evaluated before and after medication. Through this, we wish to understand the efficacy of this drug in the role of improving cognitive functioning in our patients.
Subjects may randomize to this group at 12 to 24 months after transplantation. This is followed by tapered withdrawal of calcineurin inhibitor-based immunosuppression therapy over the course of 1 year.
At Severance Hospital, patients with cholelithiasis with symptoms of indigestion are divided into the Motilitone® and Gasmotin® groups. Provide sufficient oral and written explanation of the clinical trial and obtain consent from the patient who has revealed his willingness to participate. Randomization uses random numbers, and patient assignment by random numbers is managed by a third party who does not have direct contact with the patient or clinical history, and after obtaining consent, the group according to the random number is given and medication is given. It is provided to. Each drug is prescribed for 6 months. The symptom score check should be completed at the first outpatient visit(3 months after administration). We will Check the following items through abdominal ultrasound examination 6 months after administration.

: Gallbladder wall thickening presence and extent, number of gallstones, maximum diameter of gallstones, presence or absence of sludge. The general blood test (CBD) and general chemical test (SMA) are conducted three times at the first outpatient visit(3 months after administration), and the research expenses for 3 months and 6 months are supported by the research fund. In the final analysis, we compare the symptom scores between the two groups through the Student T-test, and compare the blood test and ultrasound using the Chi-square test. We want to confirm the following three things through this study. ① In patients with cholelithiasis with symptoms of dyspepsia, prospective data on the degree of symptom improvement following motilitone administration can be obtained. ② It is possible to evaluate the degree of relief or exacerbation of gallstones through ultrasound examination. ③ It is expected that it will be effective in improving symptoms and alleviating cholelithiasis in patients with dyspeptic cholelithiasis due to increased gallbladder contractility of motilitone.
The HIIT sessions include brief, intermittent bouts of high-intensity exercise interspersed with periods of low-intensity exercise (active recovery).HIIT include 20 intervals of high-intensity (30-60s at rating of perceived exertion (RPE; Borg scale of 6-20) of 15 to 17) and low-intensity (1min at RPE \<10 or totally rest). The whole exercise cycle takes around 40-50 minutes.
Diet-Infection-Nutrition-Immunity (DINI) Axis identifies various environmental risk factors (in addition to the genetic risk factors) to establish molecular pathways causally linking them with NCDs and some cancers. At the same time, DINI Axis hypothesis translates into immunomodulatory therapeutic nutritional interventions to prevent and/or manage Non-communicable diseases (NCDs) and some cancers. As transmissible dysbiotic microbiota play some role in colorectal cancer (CRC), herein, we provide a therapeutic immunomodulatory nutraceutical formulation for use in patients with colorectal cancers which has the binary effects of killing cancer cells as well as pathogenic infectious risk factors for CRC. Based on DINI Axis, a plethora of products are being developed for various NCDs (such as Cardiovascular diseases, Diabetes, Stroke, PCOD, Osteoporosis, Non-alcoholic fatty liver disease (NAFLD), Autoimmune diseases, etc. and cancers (CRC, cervical cancer, breast cancer, etc.). More specifically, it also relates to formulation development for CRC and provides process for preparing the formulation.
Partial rotator cuff tears can be divided into three categories, bursa side tears, tendon tears and joint side tears. Studies have found that rotator cuff tendon tears account for 55% of partial tears, compared to the other two types of partial tears, there has been very little research on partial-thickness rotator cuff tendon tears, which has no consensus on diagnosis and treatment.
BACKGROUND: Transvenous endomyocardial biopsy is an invasive procedure which is used to diagnose rejection following an orthotopic heart transplant. Endomyocardial biopsy is widely regarded as low risk with all-cause complication rates below 5% in most safety studies. Following transplant, some patients require therapeutic anticoagulation. It is unknown whether anticoagulation increases endomyocardial biopsy bleeding risk.
METHODS: Records from 2061 endomyocardial biopsies performed for post-transplant rejection surveillance at our institution between November 2016 and August 2022 were reviewed. Bleeding complications were defined as vascular access-related hematoma or bleeding, procedure-related red blood cell transfusion, and new pericardial effusion. Relative risk and small sample-adjusted 95% confidence interval was calculated to investigate the association between bleeding complications and anticoagulation.
RESULTS AND CONCLUSIONS: The overall risk of bleeding was 1.2% (25/2061 cases). There was a statistically significant increase in bleeding among patients on intravenous (RR 4.46, CI 1.09-18.32) but not oral anticoagulants (RR .62, CI .15-2.63) compared to patients without anticoagulant exposure. There was a trend toward increased bleeding among patients taking warfarin with INR ≥ 1.8 (RR 3.74, CI .90-15.43). Importantly, no bleeding events occurred in patients taking direct oral anticoagulants such as apixaban. Based on these results, intravenous rather than oral anticoagulation was associated with a significantly higher risk of bleeding complications following endomyocardial biopsy.
A computerized system and method for determining a discharge workload score for a patient and a discharge planner is provided. A first discharge data element for a patient is received and assigned a first value. A second discharge data element for the patient is received and assigned a second value to the second discharge data element. The first and second values are utilized to determine a discharge workload score for the patient. The one or more patients for a care planner are determined. The workload score for each of the one or more patients is accessed and the workload scores are utilized to determine an overall workload score for the care planner.
<P>PROBLEM TO BE SOLVED: To provide a medicine inventory management system easily managing inventory from the manufacturing stage of medicine by transmitting information on the use amount of medicine from the user side to the manufacturer side almost in real time.  <P>SOLUTION: The medicine inventory management system 1 comprises a user terminal 10A, manufacturer terminals 20A, 30A, a server 40A in which user and manufacturer inventory information databases 41, 42 are stored, and a network 60 connecting the terminals 10A, 20A, 30A and the server 40A. The user terminal 10A has an input means 10E and a means for transmitting the input use amount data or the like to the server 40A through the network 60. The server 40A has a means for receiving data, a means for updating the user and manufacturer inventory information databases 41, 42 based on the received data, and a means for transmitting the received data to the manufacturer terminals 20A, 30A through the network 60. The manufacturer terminals 20A, 30A have means for receiving data, and means 20F, 30F for displaying the received data.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The present disclosure provides compositions and methods for making and obtaining Live Attenuated Influenza Vaccine (LAIV) compositions that can be delivered intranasally to provide protection against influenza virus infection. The LAIV strain is based on the cold-adapted, temperature sensitive and attenuated phenotype of a Master Donor Virus (MDV) comprising the surface glycoprotein genes of wild-type pandemic or seasonal influenza strains. Moreover, the LAIV strain is further suitable for growth in MDCK cells (madin dabigatran etes kidney cells). The use of eggs is avoided in large scale vaccine production. The purification process has no chromatographic step. The LAIV composition comprises one or more live attenuated influenza vaccine viruses and is free of polymers and surfactants.
Adjuvant therapy for patients with cervical cancer (CC) with intermediate-risk factors remains controversial. According to result of GOG 92 trail, adjuvant radiotherapy significantly improved recurrence-free survival in early stage cervical cancer with intermediate risks (Sedlis criteria). However, significant heterogeneity exists in Sedlis criteria, high risk of relapse and death occurred in patients with (1) lympho-vascular space invasion(LVSI+) and deep 1/3 stromal invasion;(2) LVSI(+) and middle 1/3 stromal invasion, and tumor size≥4cm when compared with other factors. In addition, multiple studies have confirmed that (3)non-squamous histology is an independent prognostic factor in early stage cervical cancer, who might be benefited from adjuvant concurrent chemoradiotherapy. As a result, The objective of the trial is to evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery. The primary endpoint of the study is the recurrence-free survival from the day of randomization.
Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system. Although there are various treatment modalities, including surgery, chemotherapy, and immune checkpoint inhibitor (ICI) therapy, some patients experience disease recurrence and metastasis with poor prognosis and dismal long-term survival. Antibody-drug conjugates (ADCs), which combine the targeting ability of antibody drugs with the cytotoxicity of chemotherapeutic drugs, have recently emerged as a prominent research focus in the development of individualized precision cancer therapy. Although ADCs have improved the overall response rate in patients with UC, their effectiveness remains limited. Currently, ADC-based combination therapies, particularly ADC combined with ICIs, have demonstrated promising efficacy. This combination approach has advanced the treatment of UC, exhibiting the potential to become the standard first-line therapy for advanced UC in the future. This article reviewed clinical trials involving ADC-based combination therapy for UC and discussed the possible challenges and future perspectives to provide guidance for the clinical treatment of UC.
Anti-SIRP[alpha] antibodies, including multi-specific anti-SIRP[alpha] antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP[alpha] and can block the interaction of CD47 on one cell with SIRP[alpha] on a phagocytic cell. Antibodies that are bispecific for SIRP[alpha] and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti SIRP[alpha] antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP[alpha] antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP[alpha] antibodies.
INTRODUCTION: Leukemia relapse following stem cell transplantation remains a significant barrier to long-term remission. Timely and balanced immune recovery after transplantation is crucial for preventing leukemia relapse.
AREAS COVERED: After an extensive literature search of PubMed and Web of Science through October 2023, we provide an overview of the dynamics of immune reconstitution and its role in controlling leukemia relapse. We also discuss strategies to promote immune reconstitution and reduce disease recurrence following allogeneic hematopoietic stem cell transplantation.
EXPERT OPINION: Immune reconstitution after transplantation has substantial potential to prevent relapse and might predict disease recurrence and prognosis. High dimensional cytometry, multi-omics, and T cell repertoire analysis allow for a more comprehensive and detailed understanding of the immune system's dynamics post-transplantation, and contribute to the identification of rare immune cell subsets or potential biomarkers associated with successful immune reconstitution or increased risk of complications. Strategies to enhance the immune system, such as adoptive immunotherapy and cytokine-based therapy, have great potential for reducing leukemia relapse after transplantation. Future research directions should focus on refining patient selection for these therapies, implementing appropriate and timely treatment, investigating combination approaches to maximize therapeutic outcomes, and achieving a robust graft-versus-leukemia (GVL) effect while minimizing graft-versus-host disease (GVHD) for optimal results.
In a controlled double-blind study conducted in the US, moxifloxacin hydrochloride tablets (400 mg once daily for ten days) were compared with cefuroxime axetil (250 mg twice daily for ten days) for the treatment of acute bacterial sinusitis. The trial included 457 patients valid for the efficacy analysis. Clinical success (cure plus improvement) at the 7 to 21 day post therapy test of cure visit was 90% for moxifloxacin and 89% for cefuroxime.

An additional non-comparative study was conducted to gather bacteriological data and to evaluate microbiological eradication in adult patients treated with moxifloxacin 400 mg once daily for seven days. All patients (n = 336) underwent antral puncture in this study. Clinical success rates and eradication/presumed eradication rates at the 21 to 37 day follow up visit were 97% (29 out of 30) for Streptococcus pneumoniae, 83% (15 out of 18) for Moraxella catarrhalis, and 80% (24 out of 30) for Haemophilus influenzae.